A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer

by Kim, Tae Won, Elme, Anneli, Kusic, Zvonko, Park, Joon Oh, Udrea, Anghel Adrian, Kim, Sun Young, Ahn, Joong Bae, Valencia, Ricardo Villalobos, Krishnan, Srinivasan, Bilic, Ante, Manojlovic, Nebojsa, Dong, Jun, Guan, Xuesong, Lofton-Day, Catherine, Jung, A Scott, Vrdoljak, Eduard
Published 2016

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab

by Fuchs, Charles S, Tabernero, Josep, Tomášek, Jiří, Chau, Ian, Melichar, Bohuslav, Safran, Howard, Tehfe, Mustapha A, Filip, Dumitru, Topuzov, Eldar, Schlittler, Luis, Udrea, Anghel Adrian, Campbell, William, Brincat, Stephen, Emig, Michael, Melemed, Symantha A, Hozak, Rebecca R, Ferry, David, Caldwell, C William, Ajani, Jaffer A
Published 2016

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

by Fayette, Jérôme, Wirth, Lori, Oprean, Cristina, Udrea, Anghel, Jimeno, Antonio, Rischin, Danny, Nutting, Christopher, Harari, Paul M., Csoszi, Tibor, Cernea, Dana, O’Brien, Paul, Hanley, William D., Kapp, Amy V., Anderson, Maria, Penuel, Elicia, McCall, Bruce, Pirzkall, Andrea, Vermorken, Jan B.
Published 2016